★ America V2AuditLine ALPHA

AuditLine › HHS OIG › Centers for Medicare and Medicaid Services

HHS OIG recommendation 19-A-07-029.02

We recommend that CMS continue to strengthen its internal controls to ensure that all PDE data for terminated drugs are rejected by updating its…

Closed ImplementedThe publisher's status, as reported by HHS Office of Inspector General in the file read .

The recommendation, in the publisher's words

We recommend that CMS continue to strengthen its internal controls to ensure that all PDE data for terminated drugs are rejected by updating its system edits with a new NSDE file on a more timely basis to reduce the likelihood of timelags that could lead to acceptance of PDE data for terminated drugs and payment for those drugs.
Responsible agency
Centers for Medicare and Medicaid Services
Issued
November 27, 2018
Report
CMS's Enhanced Controls Did Not Always Prevent Terminated Drug Utilization in Medicare Part D (A-07-16-06068) · find it at HHS OIG
Kind of report
Audit
Agency response
Concur (as recorded by the publisher)
Closed
January 31, 2020 (publisher's date)
Publisher topics
Prescription Drug

“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.

Dated history

  1. Issued by HHS OIG. (publisher's date)
  2. Closed, with status “Closed Implemented”. (publisher's date)
  3. First recorded by AuditLine. (start of AuditLine's own history for this record)

Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.

Other recommendations from this report

1 more, of which 0 are open in the publisher's file.

Source

Open this report in HHS OIG's tracker This publisher's records (CSV)

Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows, SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.